Skip to main content

nedosiran

Generic: NEDOSIRAN SODIUM·Brand: RIVFLOZA, Rivfloza

nedosiran: developed by 1 company · 2 clinical trials tracked.

nedosiran evidence translation

What we can confirm

What it means

Source-backed records connect nedosiran to DRNA; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

How could nedosiran → DRNA affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

Primary Hyperoxaluria; Primary Hyperoxaluria Type 1 (PH1)

Study sponsors

No additional listed-company sponsor is linked.

Development Pipeline (1)
CompanyPhase
Dicerna Pharmaceuticals Inc (DRNA)
Primary Hyperoxaluria; Primary Hyperoxaluria Type 1 (PH1)
Phase 2
Clinical Trials (2)

Treatment of Primary Hyperoxaluria Type 1 With Nedosiran

NCT05993416·DRNA
No longer available
Expanded AccessDicerna Pharmaceuticals, Inc., a Novo Nordisk company

A Phase 2 Open-Label Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nedosiran in Pediatric Patients From Birth to 11Years of Age With Primary Hyperoxaluria and Relatively Intact Renal Function

NCT05001269·Phase 2·DRNA
Completed

Primary endpoint: Percent Change From Baseline to Month 6 in Spot Urinary Oxalate-to-creatinine Ratio in PH1, PH2, or PH3 Participant Subgroups

Interventionalopen27 enrolledStarted 2022-02Completion 2025-0213 sites · Canada, Germany, Italy, Japan…Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Frequently asked questions

Who is developing nedosiran?

nedosiran is being developed by Dicerna Pharmaceuticals Inc.

How many clinical trials involve nedosiran?

BioSniper tracks 2 clinical trials involving nedosiran.